Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Monday25 March 2019

The Star : HITV in fight against cancer


This innovation in cancer treatment is relatively new, but the results have been encouraging, and trials at the UKM Medical Centre using HITV to fight cancer are in progress.

A FORM of immunotherapy is showing encouraging results in the treatment of stage 4 and recurrent cancer patients.

In a public forum held last Sunday at the Kuala Lumpur Convention Centre, Dr Kenichiro Hasumi, founder of Hasumi International Research Foundation and innovator of the Hasumi Immuno-Therapeutic Vaccine (HITV), shared his clinical findings on the effects of HITV on patients with stage 4 or recurrent cancer.

Read more ...

光明日報 : 接種HITV-擊退八成晚期癌瘤

guangming logo

(吉隆坡訊)隨著醫療科技的日新月異,自體免疫治療性疫苗(Human Initiated Therapeutic Vaccine,HITV)的研發,重燃了晚期癌患生存的一線希望。HITV研發者蓮見賢一郎(Kenichiro Hasumi)醫生指出,在採用HITV治療轉移性腫瘤的個案中,80%第四期癌患的腫瘤完全被消除,條件是轉移性腫瘤少於10顆,每顆小於5公分,成功率甚至高於第一、二及三期癌患。這項臨床發現已被發表在國際癌症期刊上。


早在1948年,全球尚未意識到何謂癌症免疫治療前,蓮見賢一郎的父親蓮見喜一郎(Kiichiro Hasumi)醫生已提出癌症疫苗的創見。他以病毒學說為基礎,認為癌細胞為正常細胞受到病毒感染產生突變所致,所以癌細胞膜表面存在著特殊的抗原。他相信只要萃取這個抗原,輔以免疫調節劑,就可健全癌症患者的免疫功能。於是他根據這個概念,研發出輔助治療癌症的蓮見疫苗。

Read more ...



HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks